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Introduction
The prostanoid prostacyclin plays a central role in haemostasis, acting as a potent inhibitor of platelet aggregation and as an endothelium-derived vasodilator 1; 2 . The prostacyclin receptor (IP) is abundantly expressed throughout the vasculature, including in platelets/megakaryocytes, macrophages, vascular endothelial and smooth muscle cells, various other tissues including the heart, kidney, lung, thymus, spleen and in sensory neurons of the dorsal root ganglion 2; 3 . The IP is primarily coupled to Gs/adenylyl cyclase activation, mediating prostacyclin inhibition of platelet aggregation and vascular tone 2; 3 .
The cardioprotective effects of prostacyclin within the myocardium and vasculature are well documented 4; 5 . Alterations in the levels of prostacyclin, its synthase or receptor, the IP, are associated with a range of vascular dysfunctions including stroke and myocardial infarction 6; 7 .
Multiple and frequent single nucleotide polymorphisms occur within the coding sequence of the human IP that correlate with predisposition to cardiovascular (CV) disease including enhanced intimal hyperplasia and platelet activation in deep vein thrombosis 8 . As a major product of cyclooxygenase (COX)-2, prostacyclin acts as a potent pro-inflammatory mediator and is abundantly produced during myocardial ischemia and hypoxia, offering cardioprotection 9; 10 .
Recognition of the importance of prostacyclin for haemostasis and CV integrity has been critically highlighted by various clinical trials that established that certain COXIBs, the sub-class of nonsteroidal anti-inflammatory drugs that selectively inhibit COX2, depress prostacyclin generation predisposing patients to increased risk of thrombotic stroke and myocardial infarction 11; 12 . While IP -/-null mice display normal vascular function, they exhibit enhanced thrombotic tendency in response to vascular injury in addition to reduced acute inflammatory responses 3 .
The protective role of estrogens in the heart and vasculature have also been established and gender-specific differences in the incidence of CV disease occur both clinically and in animal studies 5 . For example, hormone/estrogen replacement therapy can prevent the primary onset of coronary artery disease in post-menopausal women 5 , although such effects are not without controversy 13; 14 . The effects of estrogen are largely mediated through its binding to one of two estrogen receptor (ER)α and β subtypes, members of the nuclear receptor superfamily 15; 16 . ERα and ERβ display distinct patterns of expression and biological function largely acting as transcription factors to modulate expression of target genes by either direct binding to the estrogenresponsive element (ERE) with the consensus 5'-GGTCAnnnTGACC-3' palindromic sequence 17 or by indirect interaction with other transcription factors, such as Sp1 and Ap1
15
. Ligand-activated
ERs may, in turn, recruit co-activators such as CBP/p300, SRC-1, TIF2 or co-repressors including N-CoR and SMRT 18; 19 .
In addition to such classic genomic regulation by estrogen and analogues, more rapid nongenomic effects also occur and it is thought that some of these CV protective actions may be mediated by direct effects on the vessel wall 5; 16; 20 . Consistent with this, there is accumulating evidence that many of the cardio-protective effects of estrogen are mediated due to its increased synthesis & release of the endothelial-derived vasodilators nitric oxide and prostacyclin 21 . For example, estrogen induces the synthesis and expression of COX1, COX2 and prostacyclin synthase, resulting in up to 6-fold increases in systemic prostacyclin levels. Moreover, in the female low density lipoprotein receptor null mice (LDLR -/-), estrogen stimulated both COX2 expression and prostacyclin formation resulting in a substantial atheroprotection 22 . In the same study, further disruption of the IP gene abrogated the atheroprotective effects of estrogen and accelerated atherogenesis in the double LDLR -/-/IP -/-null mouse 22 . However, despite this, the actual molecular basis of the role of the IP in mediating such estrogen-induced atheroprotection remains to be established. Moreover, it is currently unknown whether estrogen may directly, or indeed indirectly, affect IP expression levels possibly accounting for such effects 22 and hence, critically, remains to be investigated.
The overall aim and rationale of the current study is to address this deficit by characterizing the hIP gene, focusing primarily on delineating the mechanism determining its aforementioned role in mediating the response to estrogen within the vasculature. Herein, we have uncovered a consensus cis-acting ERE in the hIP promoter critical for the transcriptional regulation of hIP expression by estrogen in a host of cells of vascular origin, including in the human endothelial EA.hy926 and megakaryocytic human erythroleukemia (HEL) 92.1.7 cell lines 23 and cultured primary human aortic smooth muscle cells (1 o hAoSMCs). The data outlined provide compelling evidence that the hIP gene is a direct target of estrogen that occurs through an ERα-dependent mechanism and, accordingly, not only provides a molecular genetic basis for understanding the modes of regulation of hIP expression in health and disease but also for the combined protective roles of estrogen and prostacyclin within the CV system.
Results
Estrogen-regulation of hIP Expression in EA.hy926 and HEL 92.1.7 cells.
The incidence of CV disease is less pronounced in women than men and this difference narrows post-menopause, consistent with the widely acknowledged atheroprotective actions of estrogens in pre-menopausal females 20; 24; 25 . However the underlying mechanisms of cardioprotection are largely unknown. In recent animal studies 22; 26 , the cardioprotective effects of estrogen in LDLR -/-mice were shown to be mediated in part by COX2-derived prostacyclin release.
Furthermore, the anti-atherogenic effects of estrogen were abrogated in IP -/-null mice and atherogenesis accelerated in double LDLR -/-/IP -/-null mice 22 .
The rationale of the current study was to establish whether estrogen may directly or indirectly regulate the human prostacyclin receptor (hIP) expression, providing a possible molecular basis accounting for some or all of these effects 22; 25 .
Initially, RT-PCR analysis was used to examine possible regulation of hIP mRNA expression by 17β-estradiol (E 2 ) in the human endothelial EA.hy926 and megakaryocytic HEL 92.1.7 cell lines, where the E 2 -responsive COX2 and -non-responsive GAP3'DH transcripts served as controls. Quantitative real-time RT-PCR analysis established that E 2 -treatment increased hIP mRNA in EA.hy926 (2.5-fold, P < 0.0001; Figure 1A ) and HEL (1.3-fold, P = 0.008; Figure 1B) cells, while pre-incubation with the transcriptional inhibitor actinomycin D (ActD), but not with the translational inhibitor cycloheximide (CHX), completely abrogated the E 2 -induction of hIP mRNA expression ( Figure 1A & 1B, respectively). Moreover, E 2 also resulted in significant increases in COX2 mRNA in both cell types but did not affect GAP3'DH mRNA expression (Supplemental
Figure 1).
Previous studies have defined the human IP promoter (here-on-in referred to as PrmIP) as nucleotides -2427 to -744, relative to the translational start codon (+1) 23 . Genetic firefly luciferase reporter assays were used herein to examine PrmIP-directed gene expression. Stimulation with E 2 resulted in concentration-dependent increases of PrmIP-directed luciferase expression in EA.hy926
and HEL cells (10 nM; 2-fold, P < 0.0001 and 1.7-fold, P = 0.0006, respectively; Figure 1C & 1D) .
In addition to its classic ERα-and/or ERβ-dependent genomic regulation, E 2 can mediate more rapid non-genomic effects such as through activation of GPR30, a member of the G protein coupled receptor superfamily 27 , and activation of the mitogen activated protein kinase (MAPK) and phosphatidyl inositol 3' kinase (PI3'K)-dependent signalling cascades 27; 28 . Hence, to establish whether those pathways might contribute to the E 2 -induction of PrmIP-directed gene expression, the effect of the p42/p44 extracellular signal-regulated kinase (ERK) and the PI3'K inhibitors PD98059
and Wortmanin, respectively, was examined. While E 2 led to a time-dependent increase in PrmIP-directed gene expression in both EA.hy926 and HEL cells, neither PD98059 nor Wortmanin significantly affected that expression in either cell type ( Figure 1E & 1F) . Furthermore, treatment with either PD98059 and Wortmannin alone had no effect whatsoever on basal PrmIP-directed luciferase expression in either cell type ( Figure 1E & 1F) . Hence, these data establish that hIP gene expression is indeed up-regulated by E 2 and that this occurs at the transcriptional level through a possible ERα/ERβ-dependent mechanism.
Determination of Estrogen Receptor Specificity. As stated, the hIP is primarily coupled to Gs-mediated adenylyl cyclase activation leading to agonist-dependent increases in cAMP generation 2; 3 . Hence, herein, the effect of E 2 on cAMP generation in HEL and EA.hy926 cells in response to the selective IP agonist cicaprost was 
Discussion
CV disease is the leading cause of morbidity and premature mortality, particularly in western societies, but coronary heart disease develops on average 10 years later in women than in men.
This time delay has been partly attributed to the protective effects of female sex hormones, in particular the estrogens 16; 20 . Mechanistic studies carried out in in vitro cell/tissue preparations and in animal studies have demonstrated that both natural and synthetic estrogens exhibit antiinflammatory and vasoprotective effects 24; 32; 33; 34; 35 . Moreover, 17β-estradiol (E 2 ) has been shown to lead to rapid endothelium-dependent and -independent dilation of coronary arteries in both women and men and to augment endothelium-dependent relaxation of coronary arteries ex vivo and to improve endothelial function 36 . The endothelium-derived prostacyclin not only plays a critical dynamic role in haemostasis and in the regulation of vascular tone but also, similar to E 2 , acts as a critical cytoprotectant within the wider CV system 21; 37 . Expression of COX1, COX2 and prostacyclin synthase and, consequently, synthesis of prostacyclin are significantly elevated in response to E 2 21 and compelling data generated in experimental animal models suggest that the anti-atherogenic effects of E 2 are mediated, at least in part, through the prostacyclin receptor/IP 22 .
Herein, the aim of the current study was to carry out a detailed mechanistic study with the specific objective of seeking clarity vis a vis the possible regulation of IP expression by E 2 as suggested, but never actually demonstrated, from the numerous observations generated from such studies in both humans and animals.
Stimulation with E 2 resulted in the up-regulation of COX2 and hIP mRNA levels and . To our knowledge, data presented herein is the first demonstration of (h)IP regulation by estrogen within the vasculature.
The . One such mechanism, exemplified by E 2 -regulation of the progesterone receptor 41 , occurs through 'direct binding' whereby the E 2 -liganded ER binds directly to a specific ERE and interacts directly with co-activator proteins and components of the RNA polymerase transcription initiation complex resulting in enhanced transcription. The second mechanism is referred to as 'tethering' whereby ER interacts with other DNA-bound transcription factor(s), and not DNA, stabilising DNA/protein interactions and increasing transcription. An example of tethering is the interaction of ERα with Sp1, conferring E 2 -responsiveness to the LDL receptor gene 42 .
The consensus cis-acting ERE was originally identified by aligning homologous sequences in the 5' flanking regions of the estrogen-regulated vitellogenin A1, A2, B1, B2 and apo-VLDLII genes 43 . The minimal ERE sequence is a 13 bp palindromic inverted repeat (IR) with the consensus 5'-GGTCAnnnTGACC-3' 17; 44 , which can act in an orientation-and distanceindependent manner and, therefore, is defined as an enhancer element 44 . In the case of the ERα subtype, extension of the length of the ERE palindrome with an A/T rich sequence, of approximately 15 nucleotides, immediately flanking the 5' ERE is particularly important in determining its binding affinity 17 . Herein, the site of action of E 2 was localised to -1682 to -1575 within the PrmIP and bioinformatic analysis revealed a near perfect ERE at -1654 with 12 bp of the 13 bp palindromic sequence identical to the consensus ERE and, notably, also containing a 5'
flanking "A/T rich sequence", optimal for ERα binding 17 . Moreover, the ERE and flanking 5'A/T enriched-region were found to be highly conserved in a host of other species including within the dog, bovine and horse IP promoters ( Figure 4C) . factor critical for regulation of the hIP in response to E 2 through a direct E 2 -ERα-ERE mechanism.
In conclusion, we have identified an evolutionary conserved cis-acting ERE critical for the transcriptional regulation of the hIP in model and primary cells derived from the human vasculature and confirm that the hIP gene is regulated by E 2 through a direct ERα-ERE-dependent mechanism.
These data provide an important molecular genetic platform for understanding the critical role of the hIP as a mediator of the atheroprotective effects of E 2 and its wider contribution to mechanisms of cardio-protection in humans. While it is appreciated that our studies are performed in cellular based systems, these molecular genetic studies are indeed likely to reflect the more physiological/clinical setting. Clinical trials involving E 2 , such as Women in Health Initiative (WHI), have led to conflicting data regarding the clinical safety of HRT as a cardio-protectant, or not, post-menopause 14 . In light of the fact that the data herein pertaining to the hIP adds to a growing list of other proteins including COX1-, COX2-and prostacyclin synthase-associated with the important vasodilator prostacyclin and which are also upregulated by E 2 , it is tempting to propose that data from the E 2 clinical trials might perhaps be re-evaluated or, indeed, any further trials involving E 2 may take a more detailed consideration of the prostanoid/prostacyclin-regulatory pathways/systems, such as within the vasculature. and were confirmed to be free of mycoplasma contamination.
Materials & Methods

Materials
Luciferase-based Genetic Reporter Plasmids
The plasmid pGL3B:PrmIP, encoding PrmIP (-2427 to -774, relative to the translation start codon at +1) from the human prostacyclin receptor (IP) in the pGL3Basic reporter vector, in addition to pGL3B:PrmIP1, pGL3B:PrmIP2, pGL3B:PrmIP3, pGL3B:PrmIP4, pGL3B:PrmIP5, pGL3B:PrmIP6 and pGL3B:PrmIP7 were previously described 23 . 0 µg) , or, as a negative control, pcDNA3.1, were transiently transfected into HEL, EA.hy926 or 1 o hAoSMCs, as described above, along with recombinant pGL3B:PrmIP2. Firefly and renilla luciferase activity was assayed after 48h using the Dual Luciferase Assay System®. Relative firefly to renilla luciferase activities (arbitrary units) were calculated as a ratio and were expressed in relative luciferase units (RLU).
A reporter gene assay was performed to investigate changes in the intracellular levels of cAMP using the method described by Fitzgerald et al. 47 with minor modifications. In brief, luciferase reporter pCRE-Luc (1 µg; Stratagene) was co-transfected with 50 ng pRL-TK into HEL, 
Western Blot Analysis
Both endogenous and ectopic expression of ERα and ERβ proteins in HEL, EA.hy926 and 1 o hAoSM cells was confirmed by western blot analysis. Briefly, whole cell protein was resolved by SDS-PAGE (10 % acrylamide gels) and transferred to polyvinylidene difluoride (PVDF) membrane according to standard methodology. Membranes were screened using anti-ERα and anti-ERβ sera in 5 % non fat dried milk in 1 x TBS (0.01 M Tris-HCl, 0.1 M NaCl, pH 7.4) for 2h at room temperature followed by washing and screening using goat anti-rabbit horseradish peroxidise followed by chemiluminescence detection. To confirm uniform protein loading, the blots were stripped and rescreened with anti-HDJ-2 antibody (Neomarkers) to detect endogenous HDJ-2 protein expression. In all cases the relative levels of ERα/ERβ expression in vehicle-or E 2 -incubated cells were normalized against HDJ-2 expression.
Electrophoretic Mobility Shift and Supershift Assays
Nuclear extract was prepared from HEL, EA.hy926 and 1 o hAoSM cells essentially as previously (2). Consensus ERE competitor; 5'-dGGATCTAGGTCACTGTGACCCCGGATC -3'. (3) Nonspecific competitor; 5'-dTGCGCCCGGCCTTCCATGCTCTTTGAC-3'. For electrophoretic mobility supershift assays, nuclear extract (2 µg total protein) was pre-incubated with 3 µg of anti-ERα or anti-ERβ sera for 1h at room temperature prior to the addition of the biotinylated ERE probe. As additional controls, nuclear extract or nuclear extract dialysis buffer (NEDB; 20 mM
Hepes, pH 7.9, 20% glycerol, 100 mM KCl, 0.4 mM PMSF, 0.5 mM EDTA, 0.2 mM EGTA and 0.2 mM EGTA; 48 ) was pre-incubated either with the vehicle (-) or with anti-ERα and anti-ERβ sera prior to incubation with the biotinylated ERE probe, as indicated.
ChIP analysis
Chromatin immunoprecipitation (ChIP) assays were performed as previously described 
Statistical Analysis
Statistical analysis of differences were analysed using the two-tailed Students' unpaired t-test or, as specifically indicated in the text, using two-way analysis of variance (ANOVA hAoSMCs pre-incubated for 24h with vehicle (V; PBS, 0.01 % EtOH; upper panels) or E 2 (10 nM; lower panels). Images are representative of three independent experiments. P-values ≤ 0.05 were considered to indicate statistically significant differences and *, **, ***, **** indicate P ≤. 0.05, 0.01, 0.001, 0.0001 for two-tailed Students' unpaired t-test analysis and ### indicates P ≤ 0.001 for ANOVA analysis, respectively. 
